# US 2014/0193473 A1 · Materials and methods for controlling vasculogenesis from endothelial colony forming cells > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193473 A1 - Document ID: US20140193473A1 - Status: Published application - Kind: A1 - Application number: 14/123,483 - Filed: 2012-06-06 - Published: 2014-07-10 - Earliest claimed: 2011-06-02 - Assignees: Indiana University Research and Technology Corporation - Inventors: Mervin C. Yoder; Paul Critser; Sherry Voytik-Harbin - Web page: https://patentgrep.com/patent/US20140193473A1 ## CPC - A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells - A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)} - A61L 27/24: Collagen - A61L 27/3808: {Endothelial cells} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) ## Abstract Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior. ## Claims ### Claim 1 A vessel forming matrix comprising: a population of endothelial colony forming cells in a polymerized matrix comprising at least one fraction of an acid soluble Type I collagen. ### Claim 2 (depends on 1) The matrix according to claim 1, wherein said at least one fraction of the acid soluble Type I collagen is selected from the group consisting of monomers having an average molecular weight of about 282 kDa and oligomers having an average molecular weight of about 603 kDa. ### Claim 3 (depends on 1) The matrix according to claim 1, wherein said at least one fraction of acid soluble Type I collagen includes a telopeptide reactive aldehyde. ### Claim 4 (depends on 1) The matrix according to claim 1, further comprising a second fraction of the acid soluble Type I collagen that differs from the at least one fraction. ### Claim 5 (depends on 4) The matrix according to claim 4, wherein the at least one fraction is an oligomer-rich fraction and the second fraction is a monomer-rich fraction. ### Claim 6 (depends on 5) The matrix according to claim 5, wherein the matrix comprises more of the oligomer-rich fraction than the monomer-rich fraction. ### Claim 7 (depends on 1) The matrix according to claim 1, wherein said at least one fraction of acid soluble Type I collagen is present in the matrix at a concentration of about 0.5 to about 3.0 mg/ml. ### Claim 8 (depends on 1) The matrix according to claim 1, wherein said population of endothelial colony forming cells is present in the matrix at a concentration of about 5×105 to about 2×106 cells/ml. ### Claim 9 A method of promoting vessel formation comprising the steps of: obtaining an engineered collagen matrix from an oligomer-rich fraction of a Type I acid soluble collagen; and seeding the matrix with a plurality of endothelial colony forming cells to form one or more vessels within the matrix. ### Claim 10 (depends on 9) The method according to claim 9, wherein the matrix is richer in Type I acid soluble collagen oligomers than in Type I acid soluble collagen monomers. ### Claim 11 (depends on 9) The method according to claim 9, wherein the average molecular weight of the collagen in the matrix is about 603 kDa. ### Claim 12 (depends on 9) The method according to claim 9, wherein the average molecular weight of the collagen in the matrix is greater than about 282 kDa. ### Claim 13 (depends on 9) The method according to claim 9, wherein the matrix has a collagen concentration of about 0.5 to about 3.0 mg/ml. ### Claim 14 (depends on 9) The method according to claim 9, wherein the obtaining step comprises isolating oligomers from the Type I acid soluble collagen. ### Claim 15 (depends on 9) The method according to claim 9, wherein the matrix is stiffer than the Type I collagen. ### Claim 16 (depends on 9) The method according to claim 9, wherein the matrix is in an unpolymerized state during the seeding step. ### Claim 17 (depends on 9) The method according to claim 9, wherein the seeding step comprises seeding the matrix with about 5×105 to about 2×106 cells/ml. ### Claim 18 (depends on 9) The method according to claim 9, further comprising the step of implanting the matrix into a diseased area of a patient. ### Claim 19 (depends on 18) The method according to claim 18, wherein the diseased area of the patient comprises an ischemic limb. ### Claim 20 (depends on 9) The method according to claim 9, wherein the obtaining step comprises independently controlling a stiffness of the matrix and a collagen concentration of the matrix.